Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 300 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.
Boscolo Bielo L, Guerini Rocco E, Trapani D, Zagami P, Taurelli Salimbeni B, Esposito A, Belli C, Crimini E, Venetis K, Munzone E, Fusco N, Criscitiello C, Marra A, Curigliano G
ESMO Open, 9(10):103731, 01 Oct 2024
Cited by: 0 articles | PMID: 39357123 | PMCID: PMC11480226
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Improving the Prognostic and Predictive Value of Circulating Tumor Cell Enumeration: Is Longitudinal Monitoring the Answer?
Fabisiewicz A, Szostakowska-Rodzos M, Grzybowska EA
Int J Mol Sci, 25(19):10612, 02 Oct 2024
Cited by: 0 articles | PMID: 39408942 | PMCID: PMC11476589
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors.
Schroeder C, Campilan B, Leary OP, Arditi J, Michles MJ, De La Garza Ramos R, Akinduro OO, Gokaslan ZL, Martinez Moreno M, Sullivan PLZ
Cancers (Basel), 16(18):3152, 14 Sep 2024
Cited by: 0 articles | PMID: 39335124 | PMCID: PMC11430692
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Estrogen-Receptor Loss and ESR1 Mutation in Estrogen-Receptor-Positive Metastatic Breast Cancer and the Effect on Overall Survival.
Westenend PJ, Meurs CJC, de Leeuw B, Akkers RC
Cancers (Basel), 16(17):3025, 30 Aug 2024
Cited by: 0 articles | PMID: 39272884 | PMCID: PMC11394627
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Exploring pathogenic SNPs and estrogen receptor alpha interactions in breast cancer: An in silico approach.
Alamri AM, Alkhilaiwi FA, Khan NU, Mashat RM, Tasleem M
Heliyon, 10(17):e37297, 31 Aug 2024
Cited by: 0 articles | PMID: 39286133 | PMCID: PMC11403482
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.
Lloyd MR, Jhaveri K, Kalinsky K, Bardia A, Wander SA
Nat Rev Clin Oncol, 21(10):743-761, 23 Aug 2024
Cited by: 0 articles | PMID: 39179659
Add to export list Review
Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges.
Piana D, Iavarone F, De Paolis E, Daniele G, Parisella F, Minucci A, Greco V, Urbani A
Int J Mol Sci, 25(16):8830, 14 Aug 2024
Cited by: 1 article | PMID: 39201516 | PMCID: PMC11354793
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives.
Ascione L, Castellano G, Curigliano G, Zagami P
Curr Opin Oncol, 36(6):465-473, 12 Aug 2024
Cited by: 0 articles | PMID: 39246179 | PMCID: PMC11460762
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Cadmium activation of wild-type and constitutively active estrogen receptor alpha.
Psaltis JB, Wang Q, Yan G, Gahtani R, Huang N, Haddad BR, Martin MB
Front Endocrinol (Lausanne), 15:1380047, 09 Aug 2024
Cited by: 0 articles | PMID: 39184142 | PMCID: PMC11341946
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed.
Kanbar K, El Darzi R, Jaalouk DE
Front Genet, 15:1434002, 31 Jul 2024
Cited by: 0 articles | PMID: 39144725 | PMCID: PMC11321987
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer.
Ye H, Lin G, Wang X
Transl Breast Cancer Res, 5:20, 25 Jul 2024
Cited by: 0 articles | PMID: 39184926 | PMCID: PMC11341998
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.
Yates ME, Waltermire H, Mori K, Li Z, Li Y, Guzolik H, Wang X, Liu T, Atkinson JM, Hooda J, Lee AV, Oesterreich S
Endocrinology, 165(10):bqae111, 01 Aug 2024
Cited by: 1 article | PMID: 39207954 | PMCID: PMC11384147
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.
Raei M, Heydari K, Tabarestani M, Razavi A, Mirshafiei F, Esmaeily F, Taheri M, Hoseini A, Nazari H, Shamshirian D, Alizadeh-Navaei R
BMC Cancer, 24(1):908, 28 Jul 2024
Cited by: 0 articles | PMID: 39069608 | PMCID: PMC11283726
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review.
Qureshi Z, Jamil A, Altaf F, Siddique R, Adilovic E, Fatima E, Shah S
Ann Med Surg (Lond), 86(8):4624-4633, 19 Jun 2024
Cited by: 0 articles | PMID: 39118705 | PMCID: PMC11305773
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.
Sutherland L, Lang J, Gonzalez-Juarbe N, Pickett BE
Curr Issues Mol Biol, 46(7):7114-7133, 06 Jul 2024
Cited by: 0 articles | PMID: 39057065 | PMCID: PMC11275280
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Public neoantigens in breast cancer immunotherapy (Review).
Sueangoen N, Thuwajit P, Yenchitsomanus PT, Thuwajit C
Int J Mol Med, 54(1):65, 21 Jun 2024
Cited by: 0 articles | PMID: 38904202 | PMCID: PMC11188978
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.
Zhang J, Liu J, Yue Y, Wang L, He Q, Xu S, Li J, Liao Y, Chen Y, Wang S, Xie Y, Zhang B, Bian Y, Dimitrov DS, Yuan Y, Zhu J
J Exp Clin Cancer Res, 43(1):173, 20 Jun 2024
Cited by: 0 articles | PMID: 38898487 | PMCID: PMC11188579
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Clinical, pathological and gene expression profiling of estrogen receptor discordance in breast cancer.
Wang X, Bao S, Jiang M, Zou X, Yin Y
Clin Transl Oncol, 26 Jun 2024
Cited by: 0 articles | PMID: 38926258
Add to export list
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
Kuemmel S, Harper-Wynne C, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Cardona A, Özyilkan Ö, Morales-Vàsquez F, Metcalfe C, Hafner M, Restuccia E, O'Shaughnessy J
BMC Cancer, 24(1):641, 24 May 2024
Cited by: 2 articles | PMID: 38789924 | PMCID: PMC11127459
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer-What Can We Learn from Breast Cancer?
Ottenbourgs T, Van Nieuwenhuysen E
Cancers (Basel), 16(10):1862, 13 May 2024
Cited by: 0 articles | PMID: 38791941 | PMCID: PMC11119209
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Overexpression of COL11A1 confers tamoxifen resistance in breast cancer.
Fu C, Duan S, Zhou X, Meng Y, Chen X
NPJ Breast Cancer, 10(1):38, 28 May 2024
Cited by: 0 articles | PMID: 38806505 | PMCID: PMC11133424
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation.
Zhuo Z, Zhang D, Lu W, Wu X, Cui Y, Zhang W, Zhang M
Oncol Res, 32(6):1093-1107, 23 May 2024
Cited by: 0 articles | PMID: 38827320 | PMCID: PMC11136689
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer.
Sharaf B, Hajahjeh A, Bani Hani H, Abdel-Razeq H
Front Oncol, 14:1385577, 10 May 2024
Cited by: 0 articles | PMID: 38800404 | PMCID: PMC11116652
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
Jiang H, Zhong J, Wang J, Song G, Di L, Shao B, Zhang R, Liu Y, Zhu A, Wang N, Li H
Cancer Med, 13(10):e7249, 01 May 2024
Cited by: 1 article | PMID: 38770648 | PMCID: PMC11106689
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martin M
Clin Cancer Res, 30(10):2233-2244, 01 May 2024
Cited by: 2 articles | PMID: 37889120 | PMCID: PMC11094424
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 300 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.

Improving the Prognostic and Predictive Value of Circulating Tumor Cell Enumeration: Is Longitudinal Monitoring the Answer?

Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors.

Estrogen-Receptor Loss and ESR1 Mutation in Estrogen-Receptor-Positive Metastatic Breast Cancer and the Effect on Overall Survival.

Exploring pathogenic SNPs and estrogen receptor alpha interactions in breast cancer: An in silico approach.

Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer.

Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges.

Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives.

Cadmium activation of wild-type and constitutively active estrogen receptor alpha.

Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed.

A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer.

ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes.

Diagnostic accuracy of ESR1 mutation detection by cell-free DNA in breast cancer: a systematic review and meta-analysis of diagnostic test accuracy.

Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review.

Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.

Public neoantigens in breast cancer immunotherapy (Review).

The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.

Clinical, pathological and gene expression profiling of estrogen receptor discordance in breast cancer.

Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer-What Can We Learn from Breast Cancer?

Overexpression of COL11A1 confers tamoxifen resistance in breast cancer.

Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation.

Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer.

Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.

Partnerships & funding